| << BACK TO SCREENING SERVICES LIST |
Inflammatory Screening – Elastase Release Assay
Neutrophil influx plays an important role in normal defence mechanisms at the site of inflammation, as well as contributing to the pathogenesis of various disorders. Neutrophil elastase, a major serine proteinase in man, is predominantly present in the azurophilic granules of neutrophils where it plays a major role in the intracellular killing of pathogens. During inflammation elastase is also released extracellularly where it can cause severe tissue damage.
Assay Principle
In GlycoMar’s inflammatory cell activation assay freshly isolated human neutrophils are stimulated with TNF-α and fMLP. The amount of elastase released by the neutrophils is measured using an elastase substrate with a colorimetric end point. This assay is used to screen compounds for their ability to inhibit neutrophil elastase release and so reduce inflammation.
Results
Elastase release is calculated as percentage relative to a standard control. Results are reported, summarized graphically, in a format agreed with the client.
Figure 1. Elastase release assay typical data presented graphically as % elastase activity relative to untreated control cells.
Figure 2. Elastase release assay dose response showing % elastase activity relative to untreated control cells ± standard error (SEM).
GlycoMar is committed to ensuring quality in all of its activities through a GLP-based Quality Assurance system.
Sample Submission
Samples can be submitted to GlycoMar by prior arrangement, in a number of formats.
Pricing is dependant on sample numbers submitted and turnaround required. Currently this is performed in 96-well microplate format offering low – medium throughput.
Standard turnaround is 2 weeks from receipt.
Please contact GlycoMar directly for a quotation, or to discuss your individual requirements:
Tel: +44 (0) 1631 559 368 E-mail: info@glycomar.com
| << BACK TO SCREENING SERVICES LIST |